Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.

Clinical lung cancer - 1 Jul 2023

Sireci Anthony N, Krein Peter M, Hess Lisa M, Khan Taha, Willey Joanne, Ayars Michael, Deyoung Kathryn, Bhaskar Sandhya, Mumuney Ganiat, Coutinho Anna

Abstract excerpt

INTRODUCTION/BACKGROUND: This study was designed to describe real-world changes in biomarker testing among patients with non-squamous, metastatic non-small cell lung cancer (mNSCLC) in a community oncology setting from 2015 to 2020. PATIENTS AND METHODS: This retrospective study randomly selected 500 adult patients diagnosed with nonsquamous mNSCLC to undergo chart review and data extraction. Data were extracted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 37080814
DOI: 10.1016/j.cllc.2023.03.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.PMID 37080814Read ↗

Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns studySemantic proximity Read ↗

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.Semantic proximity Read ↗

Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.Semantic proximity Read ↗

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.Semantic proximity Read ↗

Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare HospitalSemantic proximity Read ↗

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).Semantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy StrategiesSemantic proximity Read ↗

Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital.Semantic proximity Read ↗

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung CancerSemantic proximity Read ↗

Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.